Tina Tianning Yu, CEO , Mevion Medical Systems
As researchers continue to burn the midnight oil to find the next evolution of cancer care, the promise of precision medicine holds new hope. In the space of radiology oncology, proton therapy represents a form of precision therapy that exploits a physical phenomenon called Bragg peak, where proton spurs energy during its travel through matter with a sharp drop of the energy intensity at the end of its travel. This phenomenon has gained high stature in radiation oncology because it just targets the tumor site and spares the normal tissues from unnecessary radiation.
Even though there is great clinical promise with proton therapy, it had its fair share of hurdles in its path to successful adoption. Traditional proton therapy machines are large, multi-room medical devices that demanded a large space of about 60,000 square feet. They also required high levels of maintenance and sky-high operational costs. “After more than 50 years of dedicated work on proton therapy systems by scientists from multiple disciplines, we are finally able to accelerate the adoption of this modality by giving the industry a completely transformed version of this system, making it more accessible,” says Tina Tianning Yu, Ph.D., CEO of Mevion Medical Systems.
Mevion Medical Systems was founded to bring forth a new approach to proton therapy with superior performance while being drastically more affordable than traditional systems. Built upon the world’s only gantry-mounted proton accelerator, Mevion’s revised version of the traditional proton therapy system—the MEVION S250™ Series—is a compact single-room solution that delivers exceptional beam quality, stability, and uptime. The manifold advantages include reduced complexity with intuitive interfaces for clinicians used to traditional radiation therapy, reduced footprint of less than 2,000 square feet, lower manpower requirements, rapid deployment, and extraordinarily low capital and operating costs.
Our goal is to follow our mission in bringing this modality to many more patients, hospitals, and private practices
This novel cancer-fighting tool empowers more cancer centers to provide this remarkable cancer-fighting capability to their radiation oncologist teams. Mevion has installed more compact proton therapy systems than any other manufacturer in the U.S.
Mevion has proved its mettle in proton therapy industry by delivering the MEVION S250 Series to university hospitals for medical research for treating the most complex cases. Their longest running customer is the Siteman Cancer Center at Barnes-Jewish Hospital, a globally recognized leading oncology department in terms of academics and treatment capability as well. Last year, Siteman purchased their second Mevion system to expand their program with Mevion’s latest technologies.
Mevion also supports the practical clinical needs of private practice radiation oncologists. The world’s first and only private physician owned proton system, is a Mevion system run by the Ackerman Cancer Center in Florida.
Five of the NCI-designated comprehensive cancer centers—Siteman Cancer Center, Robert Wood Johnson University Hospital, Seidman Cancer Center at University Hospitals, Lombardi Cancer Center at MedStar Georgetown University Hospital, and Huntsman Cancer Institute at The University of Utah—are among their leading clients. By providing systems to the Maastro Proton Therapy Center in Europe and Allcure Kangtai in China, Mevion has successfully expanded its client base worldwide.
As the pioneer of compact proton therapy systems, Mevion has gained 78 percent of the market share of operating compact systems in the U.S. With each passing year, their client success and growth rate is reaching greater heights. “With an extremely empowered and passionate workforce, our goal is to follow our mission in bringing this modality to many more patients, hospitals, and private practices and make the proton therapy system more accessible and cost effective than ever,” concludes Tina.